Education

• Diplomat, American Board of Preventive Medicine, Public Health and General Preventive Medicine, American Health Foundation, New York, New York & New York Medical College, Valhalla, New York. 
• Diplomat, American Board of Pathology, Clinical Pathology, Duke University Medical Center, Durham, North Carolina
• M.D., 1983, University of Nebraska, Omaha
• Ph.D., 1974, North Carolina State University, Raleigh, Genetics & Statistics
• M.S., 1971, University of Nebraska, Lincoln, Genetics

Biography

Randall E. Harris, MD, PhD earned his PhD in genetics and statistics at North Carolina State University and his MD from the University Of Nebraska College of Medicine.  After completing medical residency in Clinical Pathology and Preventive Medicine at Duke University Medical Center, Dr. Harris was appointed Chief of Epidemiology at the American Health Foundation in New York City.  During 1990-1995, he chaired the Department of Preventive Medicine and in 1995, Dr. Harris became the founding Director of The Ohio State University School of Public Health.  His research provided early evidence that COX-2 blocking agents have significant potential for the prevention and therapy of cancer.  In 2009, Dr. Harris was elected a Fellow in the American Association for the Advancement of Science (AAAS).  His textbook, Epidemiology of Chronic Disease, Global Perspectives (Jones & Bartlett Learning) is widely used by students in the fields of medicine and public health.

Research Interest

Cancer, Cancer Chemoprevention, Breast Cancer Screening, Cancer Biology, Cancer Biomarkers, Cancer Diagnostics, Cancer Cell Biology, Molecular Carcinogenesis, Chemoprevention, Cancer Epidemiology.

Professional Activities:

Academic Appointments And Experience

Publications

Major Textbooks

1. Global Epidemiology of Cancer Randall E. Harris (Author) Jones & Bartlett Learning, Sudbury, MA (Copyright Date: 2015) ISBN: 978-1-284-03445-5
2. Epidemiology of Chronic Disease: Global Perspectives. Randall E. Harris (Author) Jones & Bartlett Learning, Sudbury, MA (Copyright Date: 2013) ISBN-13: 9781449653286 ISBN-10:1449653286
3. Inflammation in the Pathogenesis of Chronic Diseases: The COX-2 Controversy Randall E. Harris (Editor) Series on Sub cellular Biochemistry, Volume 42 Springer, the Netherlands, April, 2007, pp 339. ISBN-10 1-4020-5687-7
4. COX-2 Blockade in Cancer Prevention and Therapy. Randall E. Harris (Editor) Beverly Teicher’s Series on Cancer Drug Discovery and Development Humana Press, Inc., Totowa, NJ, Oct 2002, pp 371. ISBN: 1-58829-010-7

Book Chapters

1. Harris RE.  Ibuprofen in the Prevention and Therapy of Cancer.  In “Ibuprofen” Ed:  KD Rainsford, Taylor and Francis Limited, London, 2015.
2. Harris RE.  Epidemiology of breast cancer. Review.  In “Encyclopedia of Cancer”.  Ed: Manfred Schwab, Springer, Germany, 2010.
3. Harris RE.  Epidemiology of prostate cancer. Review.  In “Encyclopedia of Cancer”.  Ed:  Manfred Schwab, Springer, Germany, 2010.
4. Harris RE, Beebe-Donk J, Alshafie GA.  Reduction in the Risk of Human Breast Cancer by Selective Cyclooxygenase-2 (COX-2) Inhibitors: Final Results of a Case Control Study.  In “Progress in Cancer Prevention”.  Ed: JH Bessiel, Nova Science Publishers, 2008, www. Novapublishers.com. 
5. Harris RE.  COX-2 and the Inflammogenesis of Cancer.  In “Inflammation in the Pathogenesis of Chronic Diseases:  The COX-2 Controversy”, Subcellular Biochemistry, Volume 42, Ed:  RE Harris, Springer, The Netherlands, 2007, ISBN-10 1-4020-5687-7.
6. Harris RE, Beebe-Donk JD, Alshafie GA.  Cancer chemoprevention by selective cyclooxygenase-2 (COX-2) blockade:  results of case control studies.  In “Inflammation in the Pathogenesis of Chronic Diseases:  The COX-2 Controversy”, Subcellular Biochemistry, Volume 42, Ed:  RE Harris, Springer, The Netherlands, 2007, ISBN-10 1-4020-5687-7.
7. Harris RE.  Epidemiology of breast cancer and nonsteroidal anti-inflammatory drugs: extension of the dietary fat hypothesis of breast cancer. In “COX-2 Blockade in Cancer Prevention and Therapy”, Ed: RE Harris, Humana, Inc, Totowa, NJ, 2002.
8. Abou-Issa HM, Alshafie GA, Harris RE.  Chemoprevention of breast cancer by nonsteroidal anti-inflammatory drugs and selective COX-2 blockade in animals.  In “COX-2 Blockade in Cancer Prevention and Therapy”, Ed: RE Harris, Humana, Inc, Totowa, NJ, 2002.
9. Harris RE.  Cyclooxygenase (COX-2) Blockade in cancer prevention and therapy: widening the scope of impact.  In “COX-2 Blockade in Cancer Prevention and Therapy”, Ed: RE Harris, Humana, Inc, Totowa, NJ, 2002.

Peer Reviewed Publications

1. Harris RE. Effects of mass selection and irradiation in corn (Zea Mays L.) measured by random S1 lines and their topcrosses.  M.S. Thesis, 1971, University of Nebraska, Department of Genetics.
2. Harris RE, Gardner CO, Compton WA.  Effects of mass selection and irradiation in corn measured by random S1 lines and their testcrosses.  Crop Sci 12:594‑598, 1972.
3. Harris RE. On the control and inheritance of prolificacy in Zea Mays L., Ph.D. Thesis, 1974, N.C. State University, Department of Genetics.
4. Harris, RE, Moll RH, Stuber CW.  Control and inheritance of prolificacy in maize.  Crop Sci 16:843‑850, 1976.
5. Lynch HT, Saldivar VA, Guirgis HA, Harris RE.  Familial Hodgkin's disease and associated cancer.  A clinical‑pathologic study.  Cancer 38(5):2033‑2041, Nov 1976.
6. Corey LA, Kang KW, Christian JC, Norton JA, Harris RE, Nance WE.  Effects of chorion type on variation in cord blood cholesterol of monozygotic twins.  Am J Hum Genet 28:433‑441, 1976.
7. Lynch HT, Harris RE,  Guirgis HA, Lynch PM, Maloney K, Rankin L, Lynch J.  Early  age of onset and familial breast cancer.  Lancet 1976 Sep 18;2(7986: 525-527. 
8. Lynch HT, Guirgis HA, Lynch PM, Harris RE.  Familial cancer syndromes: a survey.  Cancer 39(4 Suppl): 1867‑1881, Apr 1977.  
9. Lynch HT, Lynch PM, Harris RE.  Proximal colon cancer in familial carcinoma of the colon exclusive of familial polyposis coli.  Lancet 1(8025):  1306‑1307, 18 Jun 1977.
10. Guirgis HA, Lynch HT, Harris RE.  Fetal antigens as a component of a carcinogenic index of cancer susceptibility.  Proceedings of Fifth International Meeting on Carcinoembryonic Proteins. Aug 1977
11. Lynch HT, Guirgis HA, Harris RE.  Familial susceptibility to lung cancer and chronic obstructive pulmonary disease.  Lancet 2(8042):815, 15 Oct 19, 1977.
12. Lynch HT, Teraski PI, Guirgis HA, Sherard BD, Androsh KL, Harris RE, King MC, Petrakis N, Lynch J, Maloney K, Rankin L, Lynch PM, Elston R, Mulcahy G, Platt R. HLA in breast cancer‑prone families and the cancer family syndrome.  Prog Clin Biol Res 16:149‑162, 1977
13. Harris RE, Lynch HT, Lemon HM, Carney K.  Multiple primary malignant neoplasms and familial breast cancer. Proceedings of the American Association for Cancer Research 18:192, 1977
14. Lynch HT, Harris RE, et al.  Role of heredity in multiple primary cancer. Cancer 40:1849‑1854, 1977.
15. Lynch HT, Harris RE, et al.  Management of hereditary site‑specific colon cancer.  Arch Surg 112:170‑174, 1977.
16. Lynch HT, Harris RE, et al.   The surgeon, genetics, and cancer control:  the cancer family syndrome.  Ann Surg 185:435‑440, 1977. 
17. Lynch PM, Lynch HT, Harris RE.  Hereditary proximal colonic cancer.  Dis Colon Rectum 20:661‑668, 1977.
18. Guirgis HA, Lynch HT, Mate T, Harris RE. Aryl‑hydrocarbon hydroxylase activity in lymphocytes from lung cancer patients and normal controls.  Oncology 33:105‑109, 1977.
19. Frichot BC, Lynch HT, Guirgis HA, Harris RE, Lynch JF.  New cutaneous phenotype in familial malignant melanoma.  Lancet. 1977 Apr 16;1(8016):864-865.
20. Lynch HT, Organ CH Jr, Harris RE, Guirgis HA, Lynch PM, Lynch JF.  Familial cancer: implications for surgical management of high‑risk patients.  Surgery 83(1):104‑113, Jan 1978.
21. Lynch HT, Harris RE, Organ CH, Lynch JF.  Familial indications for prophylactic surgery in breast‑cancer‑prone families.  Lancet 1(8058): 265, 4 Feb 1978.
22. Aarons SP, Albano, WA, Harris RE, Organ CH.  The peripheral lymphocyte count as an aid in the clinical staging of lung cancer.  Ann Surg 187(3): 248‑250, Mar 1978.
23. Lynch HT, Bardawil WA, Harris RE, et al.  Multiple primary cancers and prolonged survival: familial colonic and endometrial cancers.  Dis Colon Rectum 21(3):165‑168, Apr 1978.
24. Lynch HT, Mulcahy GM, Harris RE, et al.  Genetic and pathologic findings in a kindred with hereditary sarcoma, breast cancer, brain tumors, leukemia, lung, laryngeal, and adrenal cortical carcinoma.  Cancer 41(5):2055‑2064, May 1978.
25. Lynch HT, Bachenberg K, Harris RE, Becker W.  Hereditary atrial septal defect.  update of a large kindred.  Am J Dis Child 132(6):600‑604, Jun 1978.
26. Lynch HT, Lynch PM, Harris RE.  Minimal genetic findings and their cancer control implications.  A family with the cancer family syndrome.  JAMA 240 (6): 535‑538, 11 Aug 1978.
27. Lynch HT, Harris RE, Organ CH, Lynch JF.  Management of familial breast cancer. I. Biostatistical‑genetic aspects and their limitations as derived from a familial breast cancer resource.  Arch Surg 113(9):1053‑1058, Sept 1978
28. Lynch HT, Harris, RE, Organ CH, Lynch JF.  Management of familial breast cancer II. Case reports, pedigrees, genetic counseling, and team concept.  Arch Surg 113(9):1061‑1067, Sept 1978. 
29. Guirgis HA, Lynch HT, Harris RE, Vandevoorde JP.  Carcinoembryonic antigen (CEA) in the cancer family syndrome.  Cancer 52(3 Suppl):1574‑1578, Sept 1978.  
30. Harris RE, Lynch, HT, Guirgis HA.  Familial breast cancer: risk to the contralateral breast.  J Natl Cancer Inst 60: 955‑960, 1978.
31. Lynch HT, Harris RE, Guirgis HA.  Familial Association of breast/ovarian carcinoma.  Cancer 41:1543‑1549, 1978. [145]
32. Guirgis HA, Lynch HT, Harris RE, Vanderoorde J.  Carcinoembryonic antigen in the cancer family syndrome.  Cancer Res 38:2523‑2538, 1978.   
33. Lynch HT, Harris RE, Guirgis HA.  Early age of onset and familial breast cancer. Lancet 2 (7986):626‑627, 1978.
34. Lynch HT, Lynch PM, Follett KL, Harris RE.  Familial polyposis coli: heterogeneous polyp expression in two kindreds.  J Med Genet 16(1):1‑7, 1979.  
35. Sorrells ME, Lonnquist JH, Harris RE. Inheritance of prolificacy in maize.  Crop Sci, Vol 19, May‑Jun 1979, 301‑306.
36. Sorrells ME, Harris RE, Lonnquist JH.  Response of prolific and nonprolific maize to growth-regulating chemicals.  Crop Science, Vol 18, Sept-Oct, 1978, 783-787.  
37. Lynch HT, Harris RE, Fishman J.  Endocrine profile in a patient with familial breast cancer: a case‑control study.  Cancer 44(5): 1860‑1869, 1979.  
38. Lynch HT, Guirgis HA, Harris RE.  Clinical, genetic, and biostatistical progress in the cancer family syndrome.  Front Gastrointest Res 4:142‑150, 1979.
39. Guirgis HA, Lynch HT, Harris RE, Vandevoorde JP.  Immunochemical biological markers and hereditary‑cancer risk.  Scan J Immunol 8:647‑652, 1978.
40. Lynch HT, Guirgis HA, Harris RE.  Familial clustering of CEA in the Cancer Family syndrome, Scand J Immunology 1978 (Supp) 8:465‑470.
41. Harris RE, Al‑Rashid R.  Seasonal variation in the incidence of childhood acute lymphocytic leukemia in Nebraska.  Neb Med J 69(6):494‑499, Nov‑Dec 1984.  
42. Harris RE, Hochman HG.  Revised P‑values in testing blood group antibodies:  Fisher's exact test revisited.  Transfusion 26(6):494‑499, Nov‑Dec 1986.
43. Harris RE, Reimer KA, Crain BJ, Becsey DD, Oldham HN.  Spinal cord infarction following intra‑aortic support.  Annals of Thoracic Surgery 42:206‑207, 1986.
44. Geszler GG, Szpak CA, Harris RE, et al.  Prognostic value of peritoneal washings in patients with malignant mixed Mullerian tumors of the uterus. Am J Ob Gyn 155:83‑89, Jul 1986.
45. Toffaletti J, Christenson R, Mullins S, Harris RE. Serum lactic acid and calcium homeostasis in open heart surgery.  Clin Chem 32(10):1849‑1853, 1986.
46. Harris RE, Al‑Rashid R, Patil KD.  Seasonal patterns of childhood acute lymphocytic leukemia in the Midwestern US.  Iowa Medicine, 419‑422, Sep, 1986.
47. Harris RE, Harrell FE Jr, Patil KD, Al‑Rashid R.  The seasonal risk of pediatric/juvenile acute lymphocytic leukemia in the USA.  J Chronic Dis, 40:915‑924, 1987.
48. Harris RE, Wynder EL.  Breast cancer and alcohol consumption: a study in weak associations.  J Am Med Assoc 259(19): 2867‑2871, 1988.
49. Yu He, Harris RE, Kabat GC, Wynder EL.  Cigarette smoking, alcohol consumption, and primary liver cancer: a case‑control study in the USA. Int J Cancer 42, 325‑328, 1988.
50. La Vecchia C, Harris RE, Wynder EL.  Comparative epidemiology of cancer between the United States and Italy.  Cancer Res 48, 7285-7293, Dec, 1988.
51. Harris RE, Hebert JR, Wynder EL.  Cancer risk in male veterans utilizing the veterans administration medical system.  Cancer  64:1160‑1168; 1989.
52. Yu He, Harris RE, Wynder EL.  Case‑control study of prostate cancer and socioeconomic factors.  The Prostate 13, 317‑325; 1988.
53. Augustine A, Kabat G, Harris RE, Wynder EL.  Compensation as a risk factor for lung cancer in smokers who switch to filter cigarettes.  In "Advances in Cancer Control, Innovations and Research" AR Liss, Inc. 221‑230; 1989.
54. Wynder EL, Fujita Y, Harris RE, Hirayama T, Hiyama T.  Comparative epidemiology of cancer between the United States and Japan: a second look.  In the proceedings of MONBUSHO (Ministry of Education, Science & Culture) 1989 International Symposium, Epidemiology & Prevention of Cancer, The University of Nagoya Press, 1990.
55. Harris RE.  Training of epidemiologists in the USA.  Proceedings of 1987 workshop on epidemiology in West Germany, Karl Benz Haus, Ladenburg, W. Germany.  Statusseminar Epidemiologie in der bundesrepublik deutschland, 43‑47, 1987.
56. Harris RE, Spritz N, Wynder EL.  Studies of breast cancer and alcohol consumption.  Preventive Medicine 17, 676‑682; 1988.
57. Augustine A, Harris RE, Kabat GK, Wynder EL.  Compensation as a risk factor for lung cancer in smokers who switch from non‑filter to filter cigarettes.  Am J Publ Health 79(2), 188‑191; 1989.
58. Wynder EL, Harris RE, Haley NJ.  Population screening for plasma cholesterol: Community based results from Connecticut. Am Heart J  117, 649‑656; 1989.
59. Harris RE, Chen‑Backlund JY, Haley NJ, Wynder EL.  Population screening for plasma cholesterol: community based results from Atlanta, Georgia.  Southern Med J 82(11): 1370‑1376, 1989.
60. Boffetta P, Harris RE, Wynder EL.  Case‑control study on occupational exposure to diesel exhaust and lung cancer risk.  Am J Indust Med 17:577-591, 1990.
61. Harris RE, Langrod J, Hebert JR, Lowinson J, Zang E, Wynder EL.  Changes in AIDS risk behavior among intravenous drug abusers in New York City.  NY State J of Med 1990; Vol 90, No 3, 123-126.
62. Haley NJ, Colosimo, SG, Axelrad CA, Harris RE, Sepkovic D.  Biochemical validation of self‑reported exposure to environmental tobacco smoke.  Environ Res 49: 127‑135, 1989. 
63. Wynder EL, Harris RE.  Does alcohol consumption influence the risk of developing breast cancer? two views. In Important Advances in Oncology; eds. DeVita, VT, Hellman S & Rosenberg SA. 1989 pp 283‑293.
64. Zang AE, Wynder EL, Harris RE.  Exposure to cigarette smoke and cervical cancer.  JAMA 4(262); 499, 1989.
65. Harris RE, Haley NJ, Muscat JE, Wynder EL.  Population screening for plasma cholesterol: community-based results from Miami.   J Florida Med Assoc 76(10):853-859, 1989.
66. Wynder EL, Harris RE, Haley NJ.  Mass screening for cholesterol: a public health challenge.  Proceedings of Symposium on hypercholesterolemia as a risk factor in cardiovascular disease, Cologne, Germany, Nov, 1988.
67. Boffetta P, Harris RE, Wynder EL.  Diesel exhaust exposure and lung cancer risk.  Exp Pathol 37:32-38, 1989.
68. Harris RE, Wynder EL.  Breast cancer and alcohol consumption. JAMA (Japan) pp. 40‑45, Nov, 1988.
69. Wynder EL, Harris RE. American Health Foundation workshop on alcohol and breast cancer. Preventive Medicine 17, 665‑666; 1988.
70. Harris RE, Zang EA, Wynder EL.  Oral contraceptives and breast cancer risk: A case-control study.  Intl J Epidemiol 19(2): 240-246, 1990.
71. Harris RE, Chen‑Backlund JY, Wynder EL.  Cancer of the urinary bladder in blacks versus whites: case‑control results. Cancer 66: 2673-2680, 1990.
72. Harris RE, Langrod J, Hebert JR, Lowinson J, Zang E, Wynder EL.  Changes in AIDS risk behavior among intravenous drug abusers in New York City.  NY State J of Med Vol 90, No 3, 123-126, 1990.
73. Iyre V, Harris RE, Wynder EL.  Diesel exhaust exposure and bladder cancer risk.  Eur J Epidemiol 49-54, March 1990.
74. Muscat JE, Harris RE, Haley NJ, Wynder EL.  Population screening for plasma cholesterol: community-based results from Memphis.  J Tenn Med Assoc Vol 82, No 12, 633-639, December 1989.
75. Wynder EL, Higgins IT, Harris RE.  The wish bias.  J Clin Epidemiol Vol 43, No 6, 619-621, 1990.
76. Muscat JE, Harris RE, Haley NJ, Wynder EL.  Cigarette smoking and plasma cholesterol.  Am Heart J Vol 121, No 1, pp 141-147, January 1991.
77. Cohen LA, Choi K, Backlund JY, Harris RE, Wang CX.  Modulation of N-nitrosomethylurea induced mammary tumorigenesis by dietary fat and voluntary exercise.  In Vivo 5:333-344, 1991.
78. Wynder EL, Fujita Y, Harris RE, et al.  Comparative epidemiology of cancer between the United States and Japan: A second look. Cancer  Vol 67, No 3, 746-763, 1991. [154]
79. Namboodiri KK, Harris RE.  Hematopoietic and lymphoproliferative cancer among male veterans using the Veterans Administration Medical system.  Cancer Vol 68, No 5, 1123-1130, 1991.
80. Namboodiri KK, Hichik JB, Harris RE.  Ohio Cancer Information Service: A decade of experience.  Ohio Medicine  87:557-558, 1991.
81. Engle A, Muscat JE, Harris RE.  Nutritional Risk Factors and Ovarian Cancer.  Nutrition and Cancer  15, 239-247, 1991.
82. Yu He, Harris RE, et al.  Comparative epidemiology of cancers of the colon, rectum, prostate and breast in Shanghai, China versus the United States.  Intl J Epidemiol  20(1), 1991. [172]
83. Rosemurgy AS, Hart MB, Murphy CG, Albrink MH, Piazza A, LeParc GF, Harris RE.  Infection after injury: Association with blood transfusion.  Am Surg 58 (2): 104-107.
84. Higgins ITT, Harris RE, Wynder EL.  On the epidemiology of diesel exhaust and lung and bladder cancer--A critical review.  Archives of Env Hlth 47: 364-369, 1992.
85. Muscat JE, Harris RE, Haley NJ, Wynder EL.  A cholesterol reduction demonstration project: results from a challenge between two cities.  J Miss State Med Assn  33:87-94, March, 1992.
86. Harris RE, Namboodiri KK, Wynder EL.  Breast cancer risk: Effects of estrogen replacement therapy and body mass.  J Natl Cancer Inst  84 (20) 1575-1582, 1992.
87. Harris RE, Namboodiri KK.  "Breast Cancer Risk From Diet, Tobacco, and Alcohol:  vanishing risk".  JAMA  April 14, 1993 Vol 269, No. 14, pp 1791-1792.
88. Harris RE, Zang EA, Anderson JI, Wynder EL.  Race and sex differences in lung cancer risk associated with cigarette smoking.  Intl J Epidemiol  22(4), pp. 592-599, 1993. [162]
89. Namboodiri KK, Fisher JB, Harris RE.  The Ohio Cancer Information Service: Technology transfer on clinical trials and other measures of cancer control.  J Cancer Educ  8 (3) 227-237, 1993.
90. Williams PT, Whitcomb M, Harris RE.  Generalist physicians in non-metropolitan  counties in Ohio, Arch Fam Med  3:425-428, May 1994.
91. Higgins ITT, Harris RE, Wynder EL.  On the epidemiology of diesel-exhaust and lung and bladder cancer: a critical review.  Forschungsvereinigung Automobiltechnik e.V. (FAT), Schriften Reihe NR.112, 1994.
92. Harris RE.  Approaches to the prevention and treatment of hypertension through lifestyle modification.  National Bureau of Information on Coronary Disease.  Logical Communications, Inc., Norwalk, CT, 1994.
93. Harris RE, Namboodiri KK, Stellman SD, Wynder EL.  Breast cancer and NSAID use:  heterogeneity of effect in a case-control study.  Preventive Medicine 24:119-120, 1995.
94. Harris RE, Namboodiri KK, Farrar WB.  Epidemiologic study of non-steroidal anti-inflammatory drugs and breast cancer.  Oncology Reports 2:591-592, 1995.
95. Harris RE, Namboodiri KK, Farrar WB.  Nonsteroidal anti-inflammatory drugs and breast cancer.  Epidemiology 7:203-205, 1996. [282]
96. Harris RE, Namboodiri KK, Farrar WB, Solano SM, Wynder EL.  Breast cancer risk  and estrogen replacement therapy in lean women.  JAMA, Vol 275, No. 15, April 17, 1158, 1996.
97. Kresty LA, Carmella SG, Borukhova A, Akerkar SA, Gopalakrishnan R, Harris RE, Stoner GD, and Hecht SS.  Metabolites of a tobacco-specific nitrosamine, 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone (NNK), in the urine of smokeless tobacco users: Relationship of urinary biomarkers and oral leukoplakia.  Cancer Epidemiology, Biomarkers and Prevention 5:521-525, 1996.
98. Parrett ML, Harris RE, Joarder FS, Ross MS, Clausen KP, Robertson FM.  Cyclooxygenase-2 gene expression in human breast cancer.  International Journal of Oncology 10:503-507, 1997. [196]
99. Joarder FS, Abou-Issa H, Robertson FM, Parrett ML, Alshafie G, and Harris RE.  Growth arrest of DMBA-induced mammary carcinogenesis with ibuprofen treatment in female sprague-dawley rats.  Oncology Reports 4:1271-1273, 1997.
100. Robertson FM, Parrett ML, Joarder FS, Ross M, Abou-Issa HM, Alshafie G, and Harris RE.  Ibuprofen-induced inhibition of cyclooxygenase isoform gene expression and regression of rat mammary carcinomas. Cancer Letters 122:165-175, l998.
101. Singletary S, Bevers T, Dempsey P, Farrar B, Garber J, Harris R, Helvie M, Jacobs M, Pass H, Patterson-Smith M, Tarantolo S, Venta L. Screening for and evaluation of suspicious breast lesions (NCCN practice guidelines).  Oncology 12 (11A):89-138, l998.
102. Brueggemeier RW, Quinn AL, Subimoto Y, Lin YC, Parrett ML, Joarder FS, Harris RE, Robertson FM.  Regulation of aromatase in breast cancer and correlation of aromatase and cyclooxygenase gene expression.  In  Hormonal Carcinogenesis III,            J Li, RJ Daling, SA Li, eds., Springer-Verlag, NY , 285-298, 2001.
103. Harris RE, Kasbari S, Farrar WB.  Prospective study of  nonsteroidal anti-inflammatory drugs and breast cancer.  Oncology Reports 6:71-73, 1999.
104. Harris RE, Robertson FM, Abou-Issa HM, Farrar WB, Brueggemeier R.  Genetic              induction and upregulation of cyclooxygenase (COX) and aromatase (CYP19): an extension of the dietary fat hypothesis of breast cancer.  Medical Hypotheses 52(4): 291-292, l999.
105. Harris RE, Robertson FM, Abou-Issa HM, Farrar WB, Brueggemeier R. Epidemiology of breast cancer and NSAIDs: extension of the dietary fat hypothesis.   Vision 2000, Ohio Veterinary Medicine Association, Scientific Notes (3): 493-508, 1999.
106. Alshafie GA, Harris RE, Robertson FM, Parrett ML, Ross M, Abou-Issa H. Comparative chemopreventive activity of ibuprofen and N-(4-Hydroxyphenyl) retinamide against the development and growth of rat mammary adenocarcinomas. Anticancer Research 19: 3031-3036, 1999.
107. Parrett ML, Abou-Issa HM, Alshafie G, Ross MS, Harris RE, Robertson FM Comparative ability of ibuprofen and N-(4-hydroxyphenyl) retinamide to inhibit development of rat mammary adenocarcinomas associated with differential inhibition of gene expression of cycloxygenase isoforms.  Anticancer Research 19: 5079-5086, 1999.
108. Brueggemeier RW, Quinn AL, Parrett ML, Joarder FS, Harris RE, Robertson FM. Correlation of aromatase and cyclooxygenase gene expression in human breast cancer specimens.  Cancer Letters 140: 27-35, l999. [172]
109. Nelson JE, Harris RE.  Inverse association of prostate cancer and non-steroidal anti-inflammatory drugs (NSAIDs): results of a case-control study. Oncology Reports 7:169-170, 2000.
110. Harris RE, Alshafie GA, Abou-Issa H, Seibert K.  Chemoprevention of breast cancer in rats by celecoxib, a cyclooxygenase 2 inhibitor.  Cancer Research 60, 2101-2103, 2000. [409]
111. Harris RE, Namboodiri KA, Beebe-Donk, J.  Inverse association of malignant melanoma and non-steroidal anti-inflammatory drugs (NSAIDs) in women. Oncology Reports 8: 655-657, 2001.
112. Abou-Issa HM, Alshafie GA, Seibert K, Koki AT, Masferrer JL, Harris RE.  Dose response effects of the COX-2 inhibitor, celecoxib, on the chemoprevention of mammary carcinogenesis.  Anticancer Research 21(5): 3425-3432, 2001.
113. Alshafie GA, Abou-Issa HM, Seibert K, Koki AT, Masferrer JL, Harris RE.  Comparative chemotherapeutic efficacy of the selective COX-2 inhibitor, celecoxib, in rat mammary cancer.  Oncology Reports 7 (6): 1377-1378, 2000.
114. Schuller HM, Plummer HK III, Bochsler PN, Dudrick P, Bell JL, Harris RE.  Co-expression of β-adrenergic receptors and cyclooxygenase-2 in pulmonary adenocarcinoma. International J Oncology 19, 445-449, 2001.
115. Harris RE, Beebe-Donk J, Schuller HM.  Chemoprevention of lung cancer by non-steroidal anti-inflammatory drugs among cigarette smokers. Oncology Reports 9:693-395, 2002.
116. Harris RE, Sparks A, McTiernan A, Anderson G, White E, Chlebowski RT, Frid D, Jackson R. Inverse association of breast cancer and nonsteroidal anti-inflammatory drugs: prospective results from the Women’s Health Initiative. Cancer Research 63, 6096-6101, 2003. [212]
117. Manson JE, Hsia J, Johnson KC, …, Harris RE, et al.   Estrogen plus progestin and the           risk of  coronary heart disease.  NEW ENGLAND JOURNAL OF MEDICINE.  349,(6):523-534. [1069]
118. Chlebowski RT, Mctiernan A, Anderson G, White, E, Harris RE, et al.  Effects of Estrogen and Progesterone on Colon Cancer in the Women’s Health Initiative.  New England Journal of Medicine 350 (10): 991-1004, 2004.
119. Harris RE.  Cyclooxygenase-2 (COX-2) blockade in cancer prevention.  Inflammo-pharmacology:  Proceedings of the 2004 International Conference, Royal Society of Medicine. 2004. 
120. Harris RE.  Non-Hodgkin’s Lymphoma and nonsteroidal anti-inflammatory drugs:  a confounding problem?  International Journal of Cancer 110 (1): 150-151, 2004.
121. Harris, RE, Beebe-Donk J.  Aspirin, ibuprofen, and other nonsteroidal anti-   inflammatory drugs (NSAIDs) in cancer prevention: a critical review (Review).  Oncology Reports 13 (4), 559-583, 2005. [208]
122. Harris RE.  Does the dose make the poison?  Science 308; 203, 2005.
123. Bevers TB, Anderson BO, Bonaccio E, Borgen PI, Buys S, Daly MB, Dempsey PJ, Farrar WB, Fleming I, Garber JE, Harris RE, Helvie M, Hoover S, Krontiras H, Shaw S, Singletary E, Sugg Skinner C, Smith ML, Tsangaris TN, Wiley EL, Williams C; National Comprehensive Cancer Network.  Breast cancer screening and diagnosis.  J Natl Compr Canc Netw. 2006 May; 4(5):480-508.
124. Harris RE, Beebe-Donk J, Alshafie GA.  Reduction in the risk of human  breast  cancer by COX-2 inhibitors.  Biomed Central Cancer (BMC) 6 (27): January 30, 2006.
125. Scott SK, Rabito FA, Price PD, Butler NN, Schwartzbaum JA, Jackson BM, Love RL, Harris RE.  Comorbidity among the morbidly obese:  a comparative study of 2002 US hospital patient discharges.  Surg Obes Relat Dis, 2 (2): 105-111, 2006.
126. Harris RE, Beebe-Donk JD, Alshafie GA.  Cancer chemoprevention by selective cyclooxygenase-2 (COX-2) blockade:  results of case control studies.  Subcellular Biochemistry 42: 83-126, 2007.
127. Harris RE. COX-2 and the inflammogenesis of cancer.  Subcellular Biochemistry 42:          193-212, 2007.
128. Harris RE.  Review: Antiangiogenesis: New Frontiers in Therapeutic Development -   IBC's Fourth Annual Symposium - 16-17 October 2006, Boston, MA.  IDrugs 9(12): 834-836, 2006.
129. Harris RE, Beebe-Donk J, Alshafie Galal. Reduction in the Risk of Human Breast Cancer by Selective Cyclooxygenase-2 (COX-2) Inhibitors: Final Results of a Case Control Study.  International Journal of Cancer Prevention 3 (1/2), 1-7, 2007.
130. Clark BR, Ferketich AK, Fisher JL, Ruymann FB, Harris RE, Wilkins JR 3rd.   Evidence of population mixing based on the geographical distribution of childhood leukemia in Ohio.   Pediatr Blood Cancer 49 (6): 797-802, 2007.
131. Harris RE, Beebe-Donk J, Alshafie GA.  Reduced risk of human lung cancer by selective cyclooxygenase-2 (COX-2) blockade:  results of a case control study.  International Journal of Biological Sciences 3(5): 328-334, 2007.
132. Harris RE, Beebe-Donk J, Alshafie GA.  Similar reductions in the risk of human colon cancer by selective and non-selective cyclooxygenase-2 (COX-2) inhibitors.  BMC Cancer 8 (237): Aug 14, 2008.
133. Harris RE. Cyclooxygenase-2 (COX-2) blockade in the chemoprevention of cancers of the colon, breast, prostate, and lung.  Inflammo-pharmacology 17, 1-13, 2009.
134. Landers TF, Harris RE, Wittum TE, Stevenson KB. Colonization with Staphylococcus aureus and methicillin-resistant S. aureus among a sample of homeless individuals, Ohio.  Infect Control Hosp Epidemiol  30(8): 2009. 801-803.
135. Bevers TB, Anderson BO, Bonaccio E, Buys S, Daly MB, Dempsey PJ, Farrar WB, Fleming I, Garber JE, Harris RE, Heerdt AS, Helvie M, Huff JG, Khakpour N, Khan SA, Krontiras H, Lyman G, Rafferty E, Shaw S, Smith ML, Tsangaris TN, Williams C, Yankeelov T; National Comprehensive Cancer Network.  Breast cancer screening and diagnosis.  2009, V.1.2010, J National Comprehensive Cancer Network 2009 Nov; 7(10):1060-1096.
136. Harris RE, Beebe J, Al Shafie GA.  Reduction in cancer risk by selective and non-selective cyclooxygenase 2 (COX-2) inhibitors.  J Exp Pharm, 4, 91-96, 2012.
137.     Bevers TB, Anderson BO, Bonzccio E, Buys S, Daly MB, Dempsey PJ, Farrar WB, Fleming I, Garber JE, Harris RE, Heerdt AS, Helvie M, Huff JG, Khakpour N, Khan SA, Krontiras H, Lyman G, Rafferty E, Shaw S, Smith ML, Tsangaris TN, Williams C, Yankeelov T (2013).  Breast Cancer Screening and Diagnosis Guidelines posted to the National Comprehensive Cancer Network (NCCN)
138. Harris RE, Casto BC, Harris ZM (2014).  Cyclooxygenase-2 and the inflammogenesis of breast cancer.  World Journal of Clinical Oncology 5(4): 677-692.
139. Hall NC, Nichols SD, Povoski SP, James IA, Wright CL, Harris RE, Schmidt CR, Muscarella P, Latchana N, Martin EW, Ellison EC (2015).  Intraoperative utilization of a portable large field of view gamma camera and handheld gamma detection probe for radioguided localization and prediction of complete surgical resection of gastrinoma:  Proof of Concept.  J Am Coll Surg 221(2), 300-308.
140. Rosemurgy A, Ross S, Ryan C, Harris R (2015).   Framework for a critical evaluation of surgical literature.  American J Surgery, 210(1), 193-198.
141. Bittoni MA, Focht BC, Clinton SK, Buckworth J, Harris RE (2015).  Prospective evaluation of C-reactive protein, smoking and lung cancer death in the Third National Health and Nutrition Examination Survey.  International J Oncology 47(4), 1537-1544.